Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Role of 68Gallium PSMA-11 in Biochemical Recurrence in Prostate Cancer and in Known Metastatic Prostate Cancer and in the Evaluation of Treatment Response After Salvage Therapy

NCT04483414 is registered in ClinicalTrials.gov with Dana Mathews as lead sponsor.

NCT NCT04483414
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04483414 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Role of 68Gallium PSMA-11 in Biochemical Recurrence in Prostate Cancer and in Known Metastatic Prostate Cancer and in the Evaluation of Treatment Response After Salvage Therapy
Lead sponsor
Dana Mathews
Phase
Phase 2
Overall status
Withdrawn
Start date
March 19, 2021
Completion date
April 5, 2023
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer, prostate cancer metastatic, prostate cancer metastatic to bone